;PMID: 1305613
;source_file_2905.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..165] = [t:47..165]
;2)section:[e:169..224] = [t:169..224]
;3)section:[e:228..283] = [t:228..283]
;4)sentence:[e:287..694] = [t:287..694]
;5)sentence:[e:695..834] = [t:695..834]
;6)sentence:[e:836..1031] = [t:836..1031]
;7)sentence:[e:1032..1164] = [t:1032..1164]
;8)sentence:[e:1165..1401] = [t:1165..1401]
;9)section:[e:1405..1449] = [t:1405..1449]

;section 0 Span:0..41
;Int J Neurosci.  1992 Feb;62(3-4):287-97.
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..14] Neurosci) (.:[14..15] .)
        (CD:[17..21] 1992) (CC:[22..29] Feb;62-LRB-) (JJ:[29..31] 3-)
        (CD:[31..33] 4-RRB-) (::[33..34] :) (CD:[34..37] 287) (::[37..38] -)
        (CD:[38..40] 97) (.:[40..41] .)))

;sentence 1 Span:47..165
;Fc gamma receptors are expressed on human neuroblastoma cell lines: lack of 
;correlation with N-myc oncogene activity.
;[47..65]:gene-protein:"Fc gamma receptors"
;[89..102]:malignancy-type:"neuroblastoma"
;[141..146]:gene-rna:"N-myc"
(SENT
  (UCP-HLN
    (S
      (NP-SBJ-1 (NN:[47..49] Fc) (SYM:[50..55] gamma) (NNS:[56..65] receptors))
      (VP (VBP:[66..69] are)
        (VP (VBN:[70..79] expressed)
          (NP-1 (-NONE-:[79..79] *))
          (PP (IN:[80..82] on)
            (NP (JJ:[83..88] human) (NN:[89..102] neuroblastoma)
                (NN:[103..107] cell) (NNS:[108..113] lines))))))
    (::[113..114] :)
    (NP
      (NP (NN:[115..119] lack))
      (PP (IN:[120..122] of)
        (NP
          (NP (NN:[124..135] correlation))
          (PP (IN:[136..140] with)
            (NP
              (NML (NN:[141..146] N-myc) (NN:[147..155] oncogene))
              (NN:[156..164] activity))))))
    (.:[164..165] .)))

;section 2 Span:169..224
;Gorini G, Ciotti MT, Starace G, Vigneti E, Raschella G.
(SEC
  (FRAG (NNP:[169..175] Gorini) (NNP:[176..177] G) (,:[177..178] ,)
        (NNP:[179..185] Ciotti) (NNP:[186..188] MT) (,:[188..189] ,)
        (NNP:[190..197] Starace) (NNP:[198..199] G) (,:[199..200] ,)
        (NNP:[201..208] Vigneti) (NNP:[209..210] E) (,:[210..211] ,)
        (NNP:[212..221] Raschella) (NNP:[222..224] G.)))

;section 3 Span:228..283
;Division of Biophysics, CRE ENEA Casaccia, Rome, Italy.
(SEC
  (FRAG (NNP:[228..236] Division) (IN:[237..239] of) (NNP:[240..250] Biophysics)
        (,:[250..251] ,) (NNP:[252..255] CRE) (NNP:[256..260] ENEA)
        (NNP:[261..269] Casaccia) (,:[269..270] ,) (NNP:[271..275] Rome)
        (,:[275..276] ,) (NNP:[277..282] Italy) (.:[282..283] .)))

;sentence 4 Span:287..694
;FcRs (Fc Receptors) have been detected on the cell surface of two human 
;neuroblastoma cell lines; IMR 32 and SK-N-SH, by immunocytochemistry and flow
; cytometric analysis, using a previously characterized polyclonal antiserum 
;raised against the Fc gamma R isolated from a human CLL line (Gorini,
;Medgyesi,  Garavini, Dorrington and Down, 1987; Rozsnay, Sarmay, Szabo,
;Medgyesi, Gorini  and Gergely, 1990).
;[287..291]:gene-protein:"FcRs"
;[293..305]:gene-protein:"Fc Receptors"
;[360..373]:malignancy-type:"neuroblastoma"
;[534..544]:gene-protein:"Fc gamma R"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[287..291] FcRs))
      (NP (-LRB-:[292..293] -LRB-)
         (NN:[293..295] Fc) (NNS:[296..305] Receptors)
        (-RRB-:[305..306] -RRB-)))
    (VP (VBP:[307..311] have)
      (VP (VBN:[312..316] been)
        (VP (VBN:[317..325] detected)
          (NP-1 (-NONE-:[325..325] *))
          (PP-LOC (IN:[326..328] on)
            (NP
              (NP (DT:[329..332] the) (NN:[333..337] cell)
                  (NN:[338..345] surface))
              (PP (IN:[346..348] of)
                (NP
                  (NP (CD:[349..352] two) (JJ:[353..358] human)
                      (NN:[360..373] neuroblastoma) (NN:[374..378] cell)
                      (NNS:[379..384] lines))
                  (::[384..385] ;)
                  (NP
                    (NP (NN:[386..389] IMR) (CD:[390..392] 32))
                    (CC:[393..396] and)
                    (NP (NN:[397..404] SK-N-SH)))))))
          (,:[404..405] ,)
          (PP-MNR (IN:[406..408] by)
            (NP
              (NP (NN:[409..428] immunocytochemistry)
                (NML-2 (-NONE-:[428..428] *P*)))
              (CC:[429..432] and)
              (NP (NN:[433..437] flow) (JJ:[439..449] cytometric)
                (NML-2 (NN:[450..458] analysis)))))
          (,:[458..459] ,)
          (S-MNR
            (NP-SBJ (-NONE-:[459..459] *))
            (VP (VBG:[460..465] using)
              (NP
                (NP (DT:[466..467] a)
                  (ADJP (RB:[468..478] previously)
                        (VBN:[479..492] characterized))
                  (JJ:[493..503] polyclonal) (NN:[504..513] antiserum))
                (VP (VBN:[515..521] raised)
                  (NP (-NONE-:[521..521] *))
                  (PP (IN:[522..529] against)
                    (NP
                      (NP (DT:[530..533] the)
                         (NN:[534..536] Fc) (SYM:[537..542] gamma)
                         (NN:[543..544] R))
                      (VP (VBN:[545..553] isolated)
                        (NP (-NONE-:[553..553] *))
                        (PP (IN:[554..558] from)
                          (NP (DT:[559..560] a) (JJ:[561..566] human)
                              (NN:[567..570] CLL) (NN:[571..575] line)
                            (PRN (-LRB-:[576..577] -LRB-)
                              (FRAG (NNP:[577..583] Gorini) (,:[583..584] ,)
                                    (NNP:[585..593] Medgyesi) (,:[593..594] ,)
                                    (NNP:[596..604] Garavini) (,:[604..605] ,)
                                    (NNP:[606..616] Dorrington)
                                    (CC:[617..620] and) (NNP:[621..625] Down)
                                    (,:[625..626] ,) (CD:[627..631] 1987))
                              (::[631..632] ;)
                              (FRAG (NNP:[633..640] Rozsnay) (,:[640..641] ,)
                                    (NNP:[642..648] Sarmay) (,:[648..649] ,)
                                    (NNP:[650..655] Szabo) (,:[655..656] ,)
                                    (NNP:[657..665] Medgyesi) (,:[665..666] ,)
                                    (NNP:[667..673] Gorini) (CC:[675..678] and)
                                    (NNP:[679..686] Gergely) (,:[686..687] ,)
                                    (CD:[688..692] 1990))
                              (-RRB-:[692..693] -RRB-))))))))))))))
    (.:[693..694] .)))

;sentence 5 Span:695..834
;FcR is expressed on all the cells of both lines at least at  the same level
;as on the HL60 promyelocyte cell line used as positive control.
;[695..698]:gene-protein:"FcR"
(SENT
  (S
    (NP-SBJ-1 (NN:[695..698] FcR))
    (VP (VBZ:[699..701] is)
      (VP (VBN:[702..711] expressed)
        (NP-1 (-NONE-:[711..711] *))
        (PP-LOC (IN:[712..714] on)
          (NP
            (NP (PDT:[715..718] all) (DT:[719..722] the) (NNS:[723..728] cells))
            (PP (IN:[729..731] of)
              (NP (DT:[732..736] both) (NNS:[737..742] lines)))))
        (PP
          (ADVP (IN:[743..745] at) (JJS:[746..751] least))
          (IN:[752..754] at)
          (NP
            (NP (DT:[756..759] the) (JJ:[760..764] same) (NN:[765..770] level))
            (PP (IN:[771..773] as)
              (PP (IN:[774..776] on)
                (NP
                  (NP (DT:[777..780] the) (NN:[781..785] HL60)
                      (NN:[786..798] promyelocyte) (NN:[799..803] cell)
                      (NN:[804..808] line))
                  (VP (VBN:[809..813] used)
                    (NP (-NONE-:[813..813] *))
                    (PP (IN:[814..816] as)
                      (NP (JJ:[817..825] positive) (NN:[826..833] control)))))))))))
    (.:[833..834] .)))

;sentence 6 Span:836..1031
;Two electrophoretic components displaying apparent molecular masses of 70 and
;43  kDa respectively have been identified by SDS-PAGE followed by Western
;blotting  analysis of crude cell membranes.
(SENT
  (S
    (NP-SBJ-2
      (NP (CD:[836..839] Two) (JJ:[840..855] electrophoretic)
          (NNS:[856..866] components))
      (VP (VBG:[867..877] displaying)
        (NP
          (NP (JJ:[878..886] apparent) (JJ:[887..896] molecular)
              (NNS:[897..903] masses))
          (PP (IN:[904..906] of)
            (NP
              (NP (CD:[907..909] 70)
                (NML-1 (-NONE-:[909..909] *P*)))
              (CC:[910..913] and)
              (NP (CD:[914..916] 43)
                (NML-1 (NN:[918..921] kDa))))))))
    (ADVP (RB:[922..934] respectively))
    (VP (VBP:[935..939] have)
      (VP (VBN:[940..944] been)
        (VP (VBN:[945..955] identified)
          (NP-2 (-NONE-:[955..955] *))
          (PP-MNR (IN:[956..958] by)
            (NP
              (NP (NN:[959..967] SDS-PAGE))
              (VP (VBN:[968..976] followed)
                (NP (-NONE-:[976..976] *))
                (PP (IN:[977..979] by)
                  (NP-LGS
                    (NP
                      (NML (JJ:[980..987] Western) (NN:[988..996] blotting))
                      (NN:[998..1006] analysis))
                    (PP (IN:[1007..1009] of)
                      (NP (JJ:[1010..1015] crude) (NN:[1016..1020] cell)
                          (NNS:[1021..1030] membranes)))))))))))
    (.:[1030..1031] .)))

;sentence 7 Span:1032..1164
;In addition, "in situ" hybridization  experiments seem to exclude a
;correlation between FcR expression and N-myc  oncogene activity.
;[1120..1123]:gene-protein:"FcR"
;[1139..1144]:gene-rna:"N-myc"
(SENT
  (S
    (PP (IN:[1032..1034] In)
      (NP (NN:[1035..1043] addition)))
    (,:[1043..1044] ,)
    (NP-SBJ-1
      (NML
        (ADJP (``:[1045..1046] ") (FW:[1046..1048] in) (FW:[1049..1053] situ)
              ('':[1053..1054] "))
        (NN:[1055..1068] hybridization))
      (NNS:[1070..1081] experiments))
    (VP (VBP:[1082..1086] seem)
      (S
        (NP-SBJ-1 (-NONE-:[1086..1086] *))
        (VP (TO:[1087..1089] to)
          (VP (VB:[1090..1097] exclude)
            (NP
              (NP (DT:[1098..1099] a) (NN:[1100..1111] correlation))
              (PP (IN:[1112..1119] between)
                (NP
                  (NP (NN:[1120..1123] FcR) (NN:[1124..1134] expression))
                  (CC:[1135..1138] and)
                  (NP
                    (NML (NN:[1139..1144] N-myc) (NN:[1146..1154] oncogene))
                    (NN:[1155..1163] activity)))))))))
    (.:[1163..1164] .)))

;sentence 8 Span:1165..1401
;The presence of FcR in neuroblastoma could be related to a  possible
;functional role even on these cells which do not belong to the immune 
;system; moreover, they could also be exploited for a diagnostic
;characterization  of this tumor.
;[1181..1184]:gene-protein:"FcR"
;[1188..1201]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (DT:[1165..1168] The) (NN:[1169..1177] presence))
        (PP (IN:[1178..1180] of)
          (NP (NN:[1181..1184] FcR)))
        (PP (IN:[1185..1187] in)
          (NP (NN:[1188..1201] neuroblastoma))))
      (VP (MD:[1202..1207] could)
        (VP (VB:[1208..1210] be)
          (VP (VBN:[1211..1218] related)
            (NP-1 (-NONE-:[1218..1218] *))
            (PP-CLR (TO:[1219..1221] to)
              (NP (DT:[1222..1223] a) (JJ:[1225..1233] possible)
                  (JJ:[1234..1244] functional) (NN:[1245..1249] role)))
            (PP
              (ADVP (RB:[1250..1254] even))
              (IN:[1255..1257] on)
              (NP
                (NP (DT:[1258..1263] these) (NNS:[1264..1269] cells))
                (SBAR
                  (WHNP-2 (WDT:[1270..1275] which))
                  (S
                    (NP-SBJ-2 (-NONE-:[1275..1275] *T*))
                    (VP (VBP:[1276..1278] do) (RB:[1279..1282] not)
                      (VP (VB:[1283..1289] belong)
                        (PP-CLR (TO:[1290..1292] to)
                          (NP (DT:[1293..1296] the) (JJ:[1297..1303] immune)
                              (NN:[1305..1311] system)))))))))))))
    (::[1311..1312] ;)
    (S
      (ADVP (RB:[1313..1321] moreover))
      (,:[1321..1322] ,)
      (NP-SBJ-3 (PRP:[1323..1327] they))
      (VP (MD:[1328..1333] could) (RB:[1334..1338] also)
        (VP (VB:[1339..1341] be)
          (VP (VBN:[1342..1351] exploited)
            (NP-3 (-NONE-:[1351..1351] *))
            (PP (IN:[1352..1355] for)
              (NP
                (NP (DT:[1356..1357] a) (JJ:[1358..1368] diagnostic)
                    (NN:[1369..1385] characterization))
                (PP (IN:[1387..1389] of)
                  (NP (DT:[1390..1394] this) (NN:[1395..1400] tumor)))))))))
    (.:[1400..1401] .)))

;section 9 Span:1405..1449
;PMID: 1305613 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1405..1409] PMID) (::[1409..1410] :) (CD:[1411..1418] 1305613)
        (NN:[1419..1420] -LSB-) (NNP:[1420..1426] PubMed) (::[1427..1428] -)
        (NN:[1429..1436] indexed) (IN:[1437..1440] for)
        (NNP:[1441..1449] MEDLINE-RSB-)))
